Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation

Journal of the American College of Cardiology

Volumn 16, Issue 3, 1990, Pages 714-722

  Yasuda, Tsunehiro ^a   Gold, Herman K ^a   Yaoita, Hiroyuki ^a   Leinbach, Robert C ^a   Guerrero, J Luis ^a   Jang, Ik Kyung ^a   Holt, Robert ^a   Fallon, John T ^a   Collen, Desire ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBODY; ARGATROBAN; FIBRINOGEN RECEPTOR; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOT LYSIS; CORONARY REPERFUSION; DOG; HEART INFARCTION; HISTOLOGY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL;

ANIMAL; ANTIBODIES, MONOCLONAL; ANTITHROMBINS; ASPIRIN; COMPARATIVE STUDY; CORONARY CIRCULATION; CORONARY DISEASE; CORONARY THROMBOSIS; DOGS; PIPECOLIC ACIDS; PLATELET MEMBRANE GLYCOPROTEINS; RECURRENCE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR PATENCY;

EID: 0025143892     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(90)90364-U     Document Type: Article

References (41)

1. Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study
2. Randomised trial of intravenous streptokinase oral aspirin both or neither among 17787 cases of suspected acute myocardial infarction ISIS-2
3. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial
4. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early thrombolysis (ASSET)
5. Prospective randomized trial of intravenous and intracoronary streptokinase in acute myocardial infarction
6. Thrombolysis in Myocardial Infarction (TIMI) trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge
7. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase
8. Coronary thrombolysis with recombinant tissue-type plasminogen activator: patency rate and regional wall motion after 3 months
9. Thrombolytic efficacy of tissue-type plasminogen activator
10. Randomised double-blind trial of recombinant prourokinase against streptokinase in acute myocardial infarction
11. Coronary reocclusion after selective administration of streptokinase
12. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis following thrombolytic therapy in patients with acute myocardial infarction: a randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator
13. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin
14. A randomized, controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction
15. Prostaglandin E1 accelerates thrombolysis by tissue plasminogen activator
16. Adjunctive use of intracoronary prostaglandin E1 plus streptokinase in acute myocardial infarction
17. S2-serotonergic receptor inhibition (ketanserin), combined with thromboxane A2/prostaglandin H2 receptor blockade (BM 13.177): enhanced anti-platelet effect (letter)
18. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis
19. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant GPIIb/IIIa antibody in a canine preparation
20. The role of thrombin and thromboxane A2 in vascular reocclusion following coronary thrombolysis with tissue-type plasminogen activator
21. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone
22. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor
23. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition
24. Acceleration of reperfusion, thrombolysis, reocclusion and bleeding induced with recombinant tissue-type plasminogen activator in a rabbit model by combination of rt-PA and a selective thrombin inhibitor, Argatroban (abstr)
25. A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis
26. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or micro environment of the platelet glycoprotein IIb/IIIa complex
27. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens
28. A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT-test)
29. Monitoring of hemostasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator
30. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to tissue-type plasminogen activator
31. Arachidonate-induced platelet aggregation in the dog
32. Inhibition of dog platelet function by in vivo infusion of F(ab′)2 fragments of a monoclonal antibody
33. Effect of dextran and aspirin on platelet adherence after transluminal angioplasty of normal canine coronary arteries
34. Thrombolytic therapy (letter)
35. Tissue-type plasminogen activator: a review of its pharmacology and therapeutic use as a thrombolytic agent
36. The pathogenesis of coronary thrombus
37. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina
38. Insights into the pathogenesis of acute ischemic syndromes
39. Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator
40. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury